Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...

Theriva Biologics ( ($TOVX) ) just unveiled an update. On December 29, 2025, Theriva Biologics reported that it received positive Scientific ...

Diabetic kidney disease is a leading cause of kidney failure worldwide, yet current treatments often slow progression ...

Diabetic kidney disease affects a growing proportion of people with diabetes and remains the leading cause of end-stage renal ...

A potential vaccine against the deadly Nipah virus has shown encouraging safety and immune responses in an early human trial, ...

The study has a two-part, placebo-controlled, double-blind, randomised, dose-escalation (single ascending dose) design.

USA: Swapping common snack foods for a modest daily portion of tree nuts curbed cravings for sweets and fast foods and lifted ...

Diabetic kidney disease is a leading cause of kidney failure worldwide, yet current treatments often slow progression sustained improvement in kidney ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Comprehensive Ingredient Analysis and Clinical Study References Compiled as Post-Holiday Search Interest in Natural ...

New Nipah vaccine shows safety and strong immune response in trials: The Lancet Study A new vaccine offers hope against one of the world’s ...